CXCR2 and pancreatic neoplasm: Notably, patients with pancreatic cancer receiving CCR2 inhibitor (targeting tumor-associated macrophages) showed increased tumor-infiltrating CXCR2+ tumor-associated neutrophils following treatment, implying a compensatory influx of an alternative myeloid subset, resulting in a persistent immunosuppressive TME and promoting therapeutic resistance [57].